Safety and efficacy of immunotherapy rechallenge in patients with kidney cancer

There are a number of immune checkpoint inhibitor drugs available for the treatment of people with metastatic renal cell carcinoma (RCC), but the efficacy and safety of treating patients with two separate lines of immunotherapy (rechallenge) is unknown. This study looked at the safety and efficacy of rechallenge with an immune checkpoint inhibitor in patients […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders

This study was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago last month. The trial looked at 103 patients with a variety of different autoimmune disorders, such as psoriasis (22%), thyroiditis (20%), rheumatoid arthritis (13%), polymyalgia rheumatica (8%), inflammatory bowel disease (6%), multiple sclerosis (3%) and lupus (3%) who […]

read more

Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer

A retrospective study using data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset looked at the efficacy of nivolumab (225 patients) and cabozantinib (53 patients) when used to treat metastatic renal cell carcinoma (RCC) in the real world. The study found similar outcomes for patients treated with nivolumab and cabozantinib in the […]

read more

Immunotherapy for genitourinary cancer in the elderly

In the following interview, Dr Bradley McGregor, a medical oncologist specialising in genitourinary malignancies from the Dana-Farber Cancer Institute in Boston, USA, discusses the use of immunotherapy for genitourinary cancers in the elderly. Dr McGregor and his team looked at various checkpoint inhibitors in genitourinary cancer patients 65 years and older. They found that there […]

read more

Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer

The results of a recent phase 2 study to evaluate the safety and efficacy of anlotinib for the first-line treatment of metastatic renal cell carcinoma (RCC) were published in The Oncologist this month. Anlotinib was developed in China, and is a new tyrosine kinase inhibitor inhibiting multiple kinases involved in the growth of new blood […]

read more

Nivolumab is safe and effective for older kidney cancer patients

Findings from an expanded access programme giving 389 metastatic renal cell carcinoma (RCC) patients access to nivolumab have been published in the journal, Renal Cell Carcinoma. Of the patients on the programme, 32% were at least 70 years of age and 18% were at least 75 years of age. The phase III CheckMate 025 trial […]

read more

Antibiotics may impair the efficacy of immunotherapy in kidney cancer

A study presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, USA, suggests that antibiotics administered less than a month before starting PD-1 or PD-L1 immune checkpoint inhibitor therapy for patients with advanced kidney cancer might impair control of tumour growth. “Recent use of antibiotics prior to immune […]

read more
Showing all 10 results
  TOP